Mode
Text Size
Log in / Sign up
Phase 2 N=52 Prevention

Intra-operative Application of HEMOPATCH to the Pancreatic Stump to Prevent Post-operative Pancreatic Fistula Following Distal Pancreatectomy

Pancreas Cancer · Pancreas Disease · Pancreas Adenocarcinoma · Pancreas; Fistula · Surgery

Enrolled (actual)
52
Serious AEs
26.9%
Results posted
Aug 2021
Primary outcome: Primary: Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF) — 13 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 2
Interventions
Hemopatch (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Sunnybrook Health Sciences Centre
Primary completion
Oct 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With a Clinically Significant Post-operative Pancreatic Fistula (POPF)
13
SECONDARY
Number of Participants With a Post-operative Pancreatic Fistula (POPF)
25
SECONDARY
Number of Participants Who Experienced Post-Operative Complications
14
SECONDARY
90-Day Mortality Count
2
SECONDARY
Average Length of Stay in Hospital
6

Summary

Despite improvements and advances in pancreas surgery, about 30-35% of patients who have pancreas surgery develop a type of complication called a pancreatic fistula. A pancreatic fistula occurs when fluid produced by the pancreas leaks into the abdomen after pancreas surgery. Patients who develop a pancreatic fistula can have poor short-term and long-term consequences.We are studying the effect of a medical device named HEMOPATCH on the development and seriousness of pancreatic fistulas. HEMOPATCH is a thin, flexible bovine protein-based pad that may improve tissue sealing where it is applied during surgery. Some small studies called case studies of between 2 and 7 patients, and two clinical trials have shown that HEMOPATCH is effective at stopping bleeding and reducing drain output after some types of surgery. However, there have been no completed clinical trials using HEMOPATCH to prevent or reduce pancreatic fistulas in patients having pancreas surgery, so we don't know if it works in this setting. Health Canada has approved the use of HEMOPATCH as a device to stop bleeding or seal other bodily fluids for procedures in which the control of bleeding or leakage of other body fluids or air by standard surgical techniques are either ineffective or impractical.

Eligibility Criteria

Inclusion Criteria

  • Scheduled to undergo distal pancreatectomy surgery that is open or laparoscopic, with or without splenectomy
  • Age ≥ 18 years
  • Able and willing to comply with study procedures and follow-up examinations contained within the written consent form

Exclusion Criteria

  • Contraindication to placement of HEMOPATCH tissue sealant including: 1) Known hypersensitivity to bovine proteins; 2) Known hypersensitivity to brilliant blue [FD&C Blue No.1 (Blue 1)]; 3) Presence of an active infection; and 4) Known pregnancy or lactation (a negative urine pregnancy test must be obtained for women of child bearing potential during the pretreatment evaluation)
  • Participating in another interventional trial that may result in co-intervention or contamination (to be determined by sponsor)
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03410914). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search